Guizhou Xinbang Pharmaceutical Management
Management criteria checks 3/4
Guizhou Xinbang Pharmaceutical's CEO is Lingzhong Kong, appointed in Aug 2016, has a tenure of 8.33 years. directly owns 0.04% of the company’s shares, worth CN¥3.67M. The average tenure of the management team and the board of directors is 9.6 years and 1.2 years respectively.
Key information
Lingzhong Kong
Chief executive officer
CN¥791.7k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 8.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 9.6yrs |
| Board average tenure | 1.2yrs |
Recent management updates
Recent updates
Here's Why Guizhou Xinbang Pharmaceutical (SZSE:002390) Can Manage Its Debt Responsibly
Dec 16
There's No Escaping Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Muted Earnings
Sep 26Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings
Jun 26These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely
May 24CEO
Lingzhong Kong (56 yo)
8.3yrs
Tenure
CN¥791,700
Compensation
Ms. Lingzhong Kong serves as General Manager of Guizhou Xinbang Pharmaceutical Co., Ltd. since August 05, 2016 and served as its Secretary of the Board and Executive Deputy General Manager. Ms. Kong has be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 8.3yrs | CN¥791.70k | 0.040% CN¥ 3.7m | |
| CFO & Deputy GM | 9.6yrs | CN¥491.70k | 0.0045% CN¥ 414.8k | |
| Deputy General Manager | no data | CN¥491.70k | 0.00046% CN¥ 42.3k | |
| Deputy GM & Secretary of the Board | 10.8yrs | CN¥491.70k | 0.00038% CN¥ 35.0k | |
| Deputy General Manager | no data | CN¥551.60k | 0.0075% CN¥ 688.0k | |
| Accounting Supervisor | no data | no data | no data |
9.6yrs
Average Tenure
55yo
Average Age
Experienced Management: 002390's management team is seasoned and experienced (9.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 10.6yrs | CN¥791.70k | 0.040% CN¥ 3.7m | |
| Independent Director | less than a year | no data | no data | |
| Shareholder Supervisor | 7.1yrs | no data | 0.0050% CN¥ 461.7k | |
| Independent Director | 3.4yrs | no data | no data | |
| Chairman | 2.6yrs | CN¥791.70k | 1.06% CN¥ 97.6m | |
| Non-Independent Director | less than a year | no data | 0.0079% CN¥ 724.8k | |
| Independent Director | 1.6yrs | CN¥40.00k | no data | |
| Supervisor | less than a year | no data | 0.00080% CN¥ 73.6k | |
| Non-Independent Director | less than a year | no data | no data | |
| Non-Independent Director | less than a year | no data | no data |
1.2yrs
Average Tenure
42yo
Average Age
Experienced Board: 002390's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 22:53 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guizhou Xinbang Pharmaceutical Co., Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhouyu Deng | BOCI Research Ltd. |
| Songtao YE | Changjiang Securities Co. LTD. |
| Yichi Zhang | China International Capital Corporation Limited |